Media

– The Phase I Clinical Study of a Continuously Infused NSAID, NTM-001, Provided Steady Plasma Levels of Ketorolac Over 24 Hours, With No Unexpected Adverse Effects – Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion Has the...

- Potential to be the First Continuously Infused NSAID to be Successfully Developed for Acute Post-Operative Pain in the US - NTM-001 is an Investigational, Alcohol-Free, Stable Formulation of Ketorolac in a Pre-Mixed Bag for Continuous Infusion with the Potential to...

Neumentum Announces Dosing of Patients in Phase I Study Evaluating Its Lead Product Candidate, NTM-001, a Non-Opioid in Development for the Management of Moderately Severe Acute Pain.

-- May 8 Type B meeting confirmed to discuss the clinical development program for lead product candidate NTM-001, which has potential to treat moderately severe acute postoperative pain that requires analgesia at the opioid level, reducing the need for opioids in the...

-- Led by proven executive team, Neumentum is dedicated to becoming a leading non-opioid analgesic and neurology specialty pharmaceutical company -- -- Type B meeting requested to discuss phase 3 program for lead product candidate NTM-001, which has the potential to...